Healthcare

CytoDyn (OTC: CYDY) Submits Completed Biologics License Application (BLA) to the FDA for Leronlimab as a Combination Therapy for Highly Treatment Experienced HIV Patients

VANCOUVER, Washington, Apr 27, 2020  — During the FDA’s review period, the Company will dedicate all resources to ensure availability of leronlimab for COVID-19 patients; Cancer programs continue with positive results VANCOUVER, Washington, April 27, 2020 […]

Newsmakers

CytoDyn to Hold Conference Call to Provide Updates on Completion of BLA Filing for HIV, Timeline for Potential Approval of Treatment for COVID-19 Patients, and Two Publications, Including The New England Journal of Medicine

VANCOUVER, Washington, Apr 24, 2020  — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that […]

Newsmakers

NexTech AR (OTC: NEXCF) Provides Update on Acquisition of Work From Home (WFH) Virtual Events Webcasting Software Company Jolokia Published: April 23, 2020 at 8:30 a.m. ET

NEW YORK and TORONTO, April 23, Apr 23, 2020 — NexTech AR Solutions (NexTech) (OTCQB: NEXCF) (CSE: NTAR) (FSE: N29), the leader in augmented reality for eCommerce and AR learning applications, is pleased to update […]

Healthcare

CytoDyn (OTC: CYDY) So. California Patients Treated with Leronlimab for COVID-19 under Emergency IND: 4 Patients with Moderate Indications Removed from Oxygen; 3 Patients Discharged from Hospital; 1 Patient Scheduled for Discharge Today; 1 Patient with Severe Indications Discharged, for Total of 5 Patients Discharged

VANCOUVER, Washington, Apr 13, 2020  — More than 25 EINDs approved by FDA for leronlimab use in COVID-19 patients Phase 2 trial – As of last week, 12 patients enrolled from 2 sites; 3 more […]

Newsmakers

Floyd Mayweather, fuboTV (OTC: FBNK) Partner in Ground-Breaking Digital Likeness Joint Venture

fuboTV (OTCQB:FBNK), FaceBank Group, Floyd Mayweather and ONE Entertainment Group, LLC today announced a ground-breaking joint venture to create and manage the world-renowned retired professional boxing champion and promoter’s digital likeness, “Virtual Mayweather.” The partnership […]

Newsmakers

CytoDyn (OTC: CYDY) Collaborating with U.K.’s Department of Health to ProvideEmergency Access to Leronlimab for Severe and Critically Ill COVID-19 Patients

CEO Nader Pourhassan will appear on FOX Business Network on April 7 at 11:00 am PT to provide an update on the Company’s two COVID-19 clinical trials and 15 patients on EIND VANCOUVER, Washington, Apr […]

Healthcare

CytoDyn (OTC: CYDY) First Two Patients Enrolled in Randomized Phase 2, COVID-19 Trial with Leronlimab; Five More Severely Ill COVID-19 Patients Treated Under Emergency IND and Two Patients Have Already Extubated

Fifteen (15) severely ill COVID-19 patients have been treated under an EIND; 7-day results from the first four patients are available and are very promising; 7-day results for the first 10 patients will be available […]

Newsmakers

FaceBank Group (OTC: FBNK) and fuboTV Announce Completion of Merger – Combined Company to Be Named fuboTV, Inc.

NEW YORK—-fuboTV, Inc., a leading live TV streaming platform, and FaceBank Group, Inc. (OTCQB: FBNK), a leading celebrity and sports focused virtual entertainment company, announced today the closing of their previously announced merger agreement. This […]

Healthcare

CytoDyn (OTC: CYDY) Completes Non-dilutive $15 Million Convertible Note Financing with Conversion Rate at $4.50 Per Share without Warrants

VANCOUVER, Washington, Mar 31, 2020  — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that […]

Healthcare

FDA Clears CytoDyn’s (OTC: CYDY) Phase 2 Randomized Trial to Treat Mild-to-Moderately Ill Coronavirus Patients with Leronlimab; Enrollment to Begin Immediately

VANCOUVER, Washington, March 31, 2020 — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the […]

Healthcare

(OTC: CYDY) Three Additional Patients with Severe COVID-19 Treated with Leronlimab in New York Medical Center Bringing the Total to 10 Patients

VANCOUVER, Washington, Mar 30, 2020 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that an […]

Healthcare

CytoDyn Files FDA-Suggested Modifications to IND and Protocol for Phase 2 Clinical Trial for COVID-19 Patients with Mild to Moderate Indications and a Second Randomized Protocol for All COVID-19 Patients in Severe Condition Will be Filed Next Week per FDA Recommendation

VANCOUVER, Washington, March 27, 2020  — CytoDyn Inc. (CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that, at the […]

Healthcare

(OTC: CYDY) Leronlimab Used in Seven Patients with Severe COVID-19 Demonstrated Promise with Two Intubated Patients in ICU, Removed from ICU and Extubated with Reduced Pulmonary Inflammation

IncellDx’s evaluation of test results from the first four patients suggests immunological benefit within three days following treatment with leronlimab on all four patients and lower level of cytokine storm, especially IL-6 and TNF-α, which […]